Clinical trials: Early Small (cT1N0) Triple Negative Breast Cancer
Early Small (cT1N0) Triple Negative Breast Cancer
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
This study aims to evaluate the efficacy and safety of preoperative Durvalumab in patients with early small (cT1N0) triple negative breast cancer tumors.
- Trial name
- POP-DURVA (NCT05215106)
- Testing
- Durvalumab
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris